Sign in

NBP on Nasdaq

NovaBridge Biosciences

NovaBridge Biosciences is a pharmaceutical preparations company in the Cayman Islands.1 It is headquartered in Rockville, Maryland.1 Its shares trade on Nasdaq under the symbol NBP.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$46.3MNet income, fiscal 20252

Compare with BioXcel Therapeutics, Inc., Polomar Health Services, Inc. or Karuna Therapeutics, or pick any stock.

  • TickerNBP on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRockville, Maryland1
  • Incorporated inCayman Islands3
  • Business addressSuite 400, 2440 Research Blvd, Rockville, Md 208503
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd was established.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-11395.1%Operating margin2
-32868.5%Net margin2
-140.7%Revenue growth, 20232
-85.6%Return on equity2
-$184.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$21.4M
  • Interest0¢$102.0K

Out of $632.0K in revenue.2 The company lost money this year.

Financial statements

Revenue67892$632.0K in 2023−85% since 2019
-$100.0M0$100.0M$200.0M$300.0M2019: $4.3M$4.3M20192020: $236.4M$236.4M2020+5387%2021: $13.8M$13.8M2021−94%2022: -$1.6M-$1.6M20222023: $632.0K$632.0K2023
Operating income92-$72.0M in 2023+36% since 2022
-$80.0M-$60.0M-$40.0M-$20.0M02022: -$53.1M-$53.1M20222023: -$72.0M-$72.0M2023+36%
Net income67892-$207.7M in 2023−0% since 2019
-$400.0M-$200.0M0$200.0M2019: -$208.6M-$208.6M20192020: $72.2M$72.2M20202021: -$365.9M-$365.9M20212022: -$371.1M-$371.1M2022+1%2023: -$207.7M-$207.7M2023−44%
Fiscal year201820192020202120222023
Revenue$4.3M6$236.4M7$13.8M8-$1.6M9$632.0K2
Cost of revenue$7.3M8$3.9M10
Research and development$120.7M6$150.9M7$190.3M8$22.5M9$21.4M2
Operating expenses$51.5M9$72.6M2
Operating income-$53.1M9-$72.0M2
Interest$430.0K6$147.0K7$08$1.0K10$102.0K5
Income before tax-$366.4M8-$141.1M9-$82.2M2
Income tax$1.9M7-$495.0K8$103.0K9$02
Net income-$208.6M6$72.2M7-$365.9M8-$371.1M9-$207.7M2
Earnings per share-$28.906$0.547-$2.098-$1.969-$1.092
Earnings per share (diluted)-$28.906$0.467-$2.098-$1.969-$1.092
Shares (weighted, basic)174.7M shares5189.8M shares9191.4M shares2
Shares (weighted, diluted)174.7M shares5189.8M shares9191.4M shares2

Compare NovaBridge Biosciences with another company

Corporate structure

NovaBridge Biosciences sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NovaBridge Biosciences

  • NovaBridge Biosciences Rockville, Maryland

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NovaBridge Biosciences reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$425.0K9 Dec 31, 2024$2.7M9 Dec 31, 2023−84.5%
Accumulated depreciation$224.0K9 Dec 31, 2024$964.0K9 Dec 31, 2023−76.8%
Property and equipment, net$140.0K2 Dec 31, 2025$201.0K2 Dec 31, 2024−30.3%
Operating-lease assets (leased space)$2.8M2 Dec 31, 2025$3.6M2 Dec 31, 2024−21.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$210.6M2 Dec 31, 2025$68.3M2 Dec 31, 2024+208.6%
Marketable securities, current$210.0K2 Dec 31, 2025$105.1M2 Dec 31, 2024−99.8%
Marketable securities, non-current$02 Dec 31, 2025$30.8M2 Dec 31, 2024−100.0%

Leadership

Who has led NovaBridge Biosciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Srishti Gupta2026–now

Chief financial officer

  1. Ming Kyler Lei2026–now
Board members and other officers (20)

Former names

  • I-MabJul 29, 2019 to Oct 28, 20253

Timeline

  1. Jul 8, 2026New chief executive Srishti Gupta becomes CEO11

Filings

221 filings to the SEC since October 2021: 6 annual reports, 36 insider forms, 18 large holders, 161 other. The latest 20:

  1. Oct 13, 20266-K EDGAR
  2. Sep 21, 20264 EDGAR
  3. Sep 18, 2026144 EDGAR
  4. Sep 11, 20264 EDGAR
  5. Sep 10, 20263 EDGAR
  6. Sep 9, 2026144 EDGAR
  7. Sep 8, 20264 EDGAR
  8. Sep 8, 20266-K EDGAR
  9. Sep 8, 20266-K EDGAR
  10. Sep 1, 20264 EDGAR
  11. Aug 25, 20264 EDGAR
  12. Aug 20, 20266-K EDGAR
  13. Aug 20, 20266-K EDGAR
  14. Aug 17, 2026S-8 EDGAR
  15. Jul 24, 20266-K EDGAR
  16. Jul 17, 20266-K EDGAR
  17. Jul 10, 20264 EDGAR
  18. Jul 10, 20264 EDGAR
  19. Jul 8, 20264 EDGAR
  20. Jul 8, 20263 EDGAR

The 221 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 1 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 18, 2026Dennis Phillip AndrewChief Medical OfficerSale8,209$0.71$5.8KForm 4
Sep 9, 2026Cao Sean WuxiongChief Bus. Development OfficerSale107,978$0.74$79.9KForm 4
Aug 31, 2026Xu Cong ClaireEVP, Clinical DevelopmentSale3,282$0.79$2.6KForm 4
Jul 6, 2026Xu Cong ClaireEVP, Clinical DevelopmentSale4,485$0.89$4.0KForm 4
Jun 18, 2026Dennis Phillip AndrewChief Medical OfficerSale8,494$0.66$5.6KForm 4
Jun 1, 2026Xu Cong ClaireEVP, Clinical DevelopmentSale3,494$3.94$13.8KForm 4
May 14, 2026Cao Sean WuxiongChief Bus. Development OfficerSale21,399$1.99$42.6KForm 4
Apr 24, 2026Hagler Mark ArnoldChief Commercial OfficerBuy230,000$2.51$577.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 49. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Hhlr Advisors, Ltd.5,980,568$11.7M1.4%No change
Morgan Stanley3,653,228$7.1M0.0%−184,970
AIHC Capital Management Ltd2,878,033$5.6M5.4%+615,100
Siren, L.L.C.2,004,739$3.9M0.1%−995,261
Marshall Wace, Llp1,231,946$2.4M0.0%New
Candriam S.C.A.1,132,563$2.2M0.0%No change
Adage Capital Partners Gp, L.l.c.1,000,000$1.9M0.0%No change
Two Sigma Investments, LP851,348$1.7M0.0%New
Renaissance Technologies LLC758,226$1.5M0.0%+485,814
BlackRock, Inc.686,208$1.3M0.0%+58,712
Citadel Advisors LLC622,831$1.2M0.0%+456,215
E Fund Management Co., Ltd.589,020$1.1M0.0%New
Exome Asset Management LLC576,960$1.1M0.7%No change
State Street Corp360,376$702.7K0.0%−9,731
Woodline Partners LP350,000$682.5K0.0%−350,000
Fiera Capital Corp315,681$615.6K0.0%No change
UBS Group AG301,780$588.5K0.0%+238,239
Barclays PLC279,019$544.1K0.0%−20,280
Taikang Asset Management (Hong Kong) Co Ltd170,931$333.3K0.0%No change
Goldman Sachs Group Inc161,321$314.6K0.0%+48,858
Alps Advisors Inc117,096$228.3K0.0%New
Dimensional Fund Advisors LP116,341$226.9K0.0%−29,981
Jpmorgan Chase & Co81,556$161.5K0.0%+24,067
Geode Capital Management, LLC68,849$134.3K0.0%No change
Headlands Technologies LLC65,183$127.1K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How NovaBridge Biosciences is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNovaBridge Biosciences1
  • CIK0001778016
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressSuite 400, 2440 Research Blvd, Rockville, MD 208501
  • Phone(301) 670 28001
  • Shares outstanding265,377,891 shares as of Dec 31, 20254
  • AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey PCAOB ID 238; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceJul 29, 20191
  • Filings325 in all: 6-K (164), 144 (21), 3 (20), 4 (15), SC 13G/A (11), 424B3 (9), SC 13G (9), 20-F (7)1
    All 35 form types

    CORRESP (7), 424B5 (6), S-8 (6), 6-K/A (5), EFFECT (5), SC 13D/A (5), UPLOAD (5), DRSLTR (3), F-1/A (3), DRS/A (2), F-1 (2), SC 13D (2), SCHEDULE 13D (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 20-F/A (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), F-3 (1), F-3ASR (1), F-6 (1), F-6EF (1), POS AM (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (20-F) Apr 7, 2026

Securities registered for trading

ClassSymbolExchange
American depositary shares, each ten(10) American depositary shares representingNBPThe Nasdaq Stock Market LLC
Ordinary shares, par value $0.0001 per shareThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Apr 7, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38